- Home
- BLRX vs EDSA Comparison
BLRX vs EDSA Comparison
Compare BLRX & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- EDSA
- Stock Information
- Founded
- BLRX 2003
- EDSA 2015
- Country
- BLRX Israel
- EDSA Canada
- Employees
- BLRX N/A
- EDSA N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- EDSA Health Care
- Exchange
- BLRX Nasdaq
- EDSA Nasdaq
- Market Cap
- BLRX 17.0M
- EDSA 15.4M
- IPO Year
- BLRX 2011
- EDSA N/A
- Fundamental
- Price
- BLRX $3.71
- EDSA $2.24
- Analyst Decision
- BLRX Strong Buy
- EDSA Strong Buy
- Analyst Count
- BLRX 2
- EDSA 2
- Target Price
- BLRX $19.00
- EDSA $13.00
- AVG Volume (30 Days)
- BLRX 40.4K
- EDSA 21.9K
- Earning Date
- BLRX 08-14-2025
- EDSA 08-08-2025
- Dividend Yield
- BLRX N/A
- EDSA N/A
- EPS Growth
- BLRX N/A
- EDSA N/A
- EPS
- BLRX N/A
- EDSA N/A
- Revenue
- BLRX $17,251,000.00
- EDSA N/A
- Revenue This Year
- BLRX N/A
- EDSA N/A
- Revenue Next Year
- BLRX N/A
- EDSA N/A
- P/E Ratio
- BLRX N/A
- EDSA N/A
- Revenue Growth
- BLRX 1.19
- EDSA N/A
- 52 Week Low
- BLRX $2.30
- EDSA $1.55
- 52 Week High
- BLRX $32.26
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- BLRX 39.17
- EDSA 52.38
- Support Level
- BLRX $3.58
- EDSA $2.02
- Resistance Level
- BLRX $4.17
- EDSA $2.28
- Average True Range (ATR)
- BLRX 0.27
- EDSA 0.13
- MACD
- BLRX -0.01
- EDSA -0.01
- Stochastic Oscillator
- BLRX 37.11
- EDSA 59.72
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.